| Literature DB >> 26159421 |
David Kozono1, Jie Li2, Masayuki Nitta1, Oltea Sampetrean3, David Gonda2, Deepa S Kushwaha1, Dmitry Merzon1, Valya Ramakrishnan2, Shan Zhu1, Kaya Zhu1, Hiroko Matsui4, Olivier Harismendy4, Wei Hua5, Ying Mao5, Chang-Hyuk Kwon6, Hideyuki Saya3, Ichiro Nakano6, Donald P Pizzo7, Scott R VandenBerg7, Clark C Chen8.
Abstract
The available evidence suggests that the lethality of glioblastoma is driven by small subpopulations of cells that self-renew and exhibit tumorigenicity. It remains unclear whether tumorigenicity exists as a static property of a few cells or as a dynamically acquired property. We used tumor-sphere and xenograft formation as assays for tumorigenicity and examined subclones isolated from established and primary glioblastoma lines. Our results indicate that glioblastoma tumorigenicity is largely deterministic, yet the property can be acquired spontaneously at low frequencies. Further, these dynamic transitions are governed by epigenetic reprogramming through the lysine-specific demethylase 1 (LSD1). LSD depletion increases trimethylation of histone 3 lysine 4 at the avian myelocytomatosis viral oncogene homolog (MYC) locus, which elevates MYC expression. MYC, in turn, regulates oligodendrocyte lineage transcription factor 2 (OLIG2), SRY (sex determining region Y)-box 2 (SOX2), and POU class 3 homeobox 2 (POU3F2), a core set of transcription factors required for reprogramming glioblastoma cells into stem-like states. Our model suggests epigenetic regulation of key transcription factors governs transitions between tumorigenic states and provides a framework for glioblastoma therapeutic development.Entities:
Keywords: epigenomics; glioblastoma; neoplastic stem cells
Mesh:
Substances:
Year: 2015 PMID: 26159421 PMCID: PMC4522819 DOI: 10.1073/pnas.1501967112
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205